Secondary hyperparathyroidism is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH) because something else in the body has gone wrong first, most often chronic kidney disease. Unlike primary hyperparathyroidism, where the glands themselves are faulty, secondary hyperparathyroidism is a compensatory response: the glands are doing exactly what they are designed to do, just too much and for too long. The distinction matters because treatment focuses not only on the glands but on fixing or managing the underlying trigger. Left unchecked, the condition can damage bones, blood vessels, and overall quality of life in ways that many patients and even some clinicians underestimate.
How the Parathyroid Glands Normally Work
Your four parathyroid glands sit behind the thyroid in your neck and have one central job: keeping blood calcium within a very tight range. They do this through a feedback loop. When blood calcium dips even slightly, the glands sense the drop through specialized calcium-sensing receptors and release more PTH. PTH then pulls calcium from bones, tells the kidneys to hold onto calcium instead of excreting it, and stimulates the kidneys to activate vitamin D, which in turn boosts calcium absorption from food. Once blood calcium returns to normal, the glands dial PTH back down.1PubMed Central. The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future In secondary hyperparathyroidism, that feedback loop is disrupted. The signal to keep pumping out PTH never fully resolves because the underlying problem persists.
Chronic Kidney Disease as the Leading Cause
The most common driver of secondary hyperparathyroidism is chronic kidney disease (CKD). As kidney function declines, several things happen almost simultaneously. The kidneys lose the ability to convert vitamin D into its active form, which means less calcium gets absorbed from the gut. At the same time, damaged kidneys cannot clear phosphorus efficiently, so phosphorus builds up in the blood. Both of these changes, low calcium and high phosphorus, push the parathyroid glands to ramp up PTH production.2PubMed Central. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management The glands don’t just work harder; they actually grow. The individual cells multiply, and the glands physically enlarge over time.3PubMed Central. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
There is another layer to this process that researchers have pieced together more recently. A hormone called FGF23, produced by bone cells, normally helps regulate phosphorus by signaling the kidneys and parathyroid glands. For FGF23 to work on the parathyroid glands, it needs a co-receptor called Klotho. As CKD progresses, Klotho levels in the parathyroid glands drop significantly, making the glands increasingly deaf to FGF23’s signal.4Kidney International. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients In early kidney disease, FGF23 can still suppress PTH release, but in advanced disease this braking mechanism fails entirely.5PubMed. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease This resistance helps explain why PTH levels can spiral upward so dramatically in patients on dialysis.
When the Glands Stop Listening to Treatment
As parathyroid glands enlarge under chronic stimulation, their internal structure changes. Early on, the overgrowth is relatively uniform, called diffuse hyperplasia, and the cells still respond reasonably well to vitamin D and calcium. Over time, though, clumps of cells can form nodules within the glands. These nodular areas have significantly fewer vitamin D receptors, which means the cells are much less responsive to vitamin D-based therapies.6PubMed. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism This progression from diffuse to nodular hyperplasia is a key turning point. It is the reason patients who initially responded well to medical treatment can gradually become resistant, requiring dose escalation or a switch to different drug classes, and sometimes surgical removal of the glands.
If the glands eventually start overproducing PTH autonomously, with blood calcium rising above normal, the condition is reclassified as tertiary hyperparathyroidism. This transition typically happens after years of unchecked secondary disease. In tertiary disease, the glands have essentially broken free of their normal feedback controls and behave more like those in primary hyperparathyroidism, driving calcium levels too high.7PubMed. Secondary and tertiary hyperparathyroidism
Non-Kidney Causes People Often Miss
While CKD gets most of the attention, secondary hyperparathyroidism also develops in people with perfectly healthy kidneys. Bariatric surgery is a growing cause. Procedures like Roux-en-Y gastric bypass reroute the digestive tract past the duodenum and upper small intestine, which are the primary sites for calcium absorption. Fat absorption also decreases, and since vitamin D is fat-soluble, less of it gets into the bloodstream. The result is the same cascade: low calcium and low active vitamin D prompt the parathyroid glands to overproduce PTH.8Mayo Clinic Proceedings. Secondary Hyperparathyroidism After Roux-en-Y Gastric Bypass: A Case Series Studies looking at patients five years after gastric bypass or duodenal switch have found that the prevalence of secondary hyperparathyroidism remains high even with standard supplementation, suggesting that typical calcium doses are not enough to compensate for the malabsorption.9PubMed. Secondary hyperparathyroidism, vitamin D sufficiency, and serum calcium 5 years after gastric bypass and duodenal switch Calcium citrate, rather than calcium carbonate, is generally preferred after these surgeries because it does not require stomach acid for absorption, and stomach acid production drops sharply after bypass.10PubMed Central. SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
Severe vitamin D deficiency from any cause, whether from limited sun exposure, malabsorption from celiac disease or inflammatory bowel disease, or simply poor dietary intake, can trigger the same chain of events. Any condition that chronically lowers blood calcium or impairs vitamin D metabolism is a potential trigger.
What It Does to Bones and Blood Vessels
The skeleton takes the biggest hit. Persistently elevated PTH accelerates bone turnover, meaning bone is broken down and rebuilt at an abnormally high rate. In severe cases this produces a condition called osteitis fibrosa cystica, in which bones develop cyst-like lesions and become fragile enough to fracture with minimal force.11International Medical Case Reports Journal. Osteitis Fibrosa Cystica; A Forgotten Manifestation of Secondary Hyperparathyroidism Due to End-Stage Renal Disease: A Case Report In children with CKD, the skeletal effects are even more consequential: excessive bone turnover interferes with normal growth, and untreated secondary hyperparathyroidism is a recognized cause of growth failure.12PubMed Central. Chronic kidney disease mineral and bone disorder in children
The cardiovascular system is the other major target. When both calcium and phosphorus levels are elevated, calcium-phosphate crystals can deposit in blood vessel walls, heart valves, and soft tissues. This vascular calcification stiffens arteries, raises blood pressure, and increases the risk of heart attacks and strokes. Animal research has shown that lowering serum phosphorus levels with phosphate binders can significantly inhibit this calcification process, highlighting how central phosphorus control is to preventing cardiovascular damage.13PubMed Central. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels
A rarer but devastating complication is calciphylaxis, in which calcium deposits form in the small blood vessels of the skin, cutting off blood flow. Patients develop intensely painful, darkened skin patches that can progress to open ulcers and gangrene. The mortality rate is high because the wounds frequently become infected. Calciphylaxis tends to occur when the calcium-phosphate product in the blood is very elevated, and its progression can require amputation.14PubMed. Calciphylaxis in secondary hyperparathyroidism. Diagnosis and parathyroidectomy
Symptoms That Patients Actually Feel
Many people with secondary hyperparathyroidism, especially in earlier stages, have no symptoms they can point to. The condition is usually detected through routine blood work. As PTH climbs higher, though, symptoms do emerge, and a prospective study of hemodialysis patients found that rising PTH levels tracked with worsening bone aches, joint stiffness, muscle soreness, itchy skin, and fatigue. The higher the PTH increase, the more pronounced these symptoms became.15PubMed. Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study Itching in particular is a major quality-of-life issue for dialysis patients, and while it has many possible causes, poorly controlled secondary hyperparathyroidism is a well-recognized contributor.
An underappreciated consequence is anemia that does not respond to the drugs normally used to stimulate red blood cell production. Elevated PTH can cause fibrosis inside the bone marrow, crowding out the cells that make red blood cells. In case reports, getting PTH under better control has resolved this type of treatment-resistant anemia completely.16PubMed Central. “Ideal” parathyroid hormone in erythropoietin-stimulating agents-resistant anemia
Why PTH Lab Results Are Trickier Than They Look
Most clinicians order a standard “intact PTH” blood test, which sounds definitive but has a significant quirk in kidney disease. The assay is designed to measure the full-length, biologically active form of PTH, but it also picks up fragments of the hormone that have been partially broken down. In healthy people this cross-reactivity is minor. In CKD patients, though, these fragments accumulate because the kidneys are not clearing them, and they can account for roughly half of what the assay reports.17Clinical Chemistry. A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples One study estimated that PTH readings in kidney failure patients need to be about 1.6 times the upper limit of normal just to reflect the same amount of truly active hormone as in someone with healthy kidneys.18The Journal of Clinical Endocrinology & Metabolism. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values
This has real clinical consequences. A dialysis patient whose PTH reads as moderately elevated might actually have nearly normal levels of the active hormone, while aggressive treatment to push that number down could tip them into a low-turnover bone state that is equally harmful. Newer “whole PTH” or “bio-intact” assays that better distinguish the active hormone from fragments exist but are not widely available, and clinical guidelines still largely rely on the standard intact assay with the caveat that results should be interpreted in context, not taken at face value.19PubMed Central. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications
Medical Treatment Options
Treatment follows a stepwise approach. The foundation is controlling phosphorus levels with diet and phosphate binders, and correcting vitamin D deficiency. Active vitamin D compounds (calcitriol and its newer analogs) directly suppress PTH production, but they come with trade-offs. Calcitriol is the oldest and most studied option, but at the doses needed to control advanced disease it tends to raise both calcium and phosphorus, which is the opposite of what you want. Paricalcitol, a newer analog, suppresses PTH with much less impact on calcium and phosphorus levels.20PubMed. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease In a head-to-head comparison of dialysis patients, paricalcitol achieved the target PTH reduction significantly faster than calcitriol, and fewer patients developed episodes of dangerously high calcium.21Kidney International. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism In patients with diabetic kidney disease who were not yet on dialysis, paricalcitol at a higher dose reduced PTH by roughly half.22PubMed Central. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study
When vitamin D analogs alone are not enough, calcimimetics are added. These drugs work on the calcium-sensing receptors on the parathyroid glands, essentially tricking the glands into thinking blood calcium is higher than it really is, which dampens PTH release. The advantage over vitamin D-based therapy is that calcimimetics lower PTH without raising calcium, phosphorus, or FGF23.23PubMed Central. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy Cinacalcet was the first oral calcimimetic available, and etelcalcetide, an intravenous form given at the end of dialysis sessions, followed.
When Surgery Becomes the Answer
Parathyroidectomy, surgical removal of most or all of the parathyroid tissue, is reserved for patients whose disease does not respond to medication or who develop severe complications like calciphylaxis, refractory bone disease, or uncontrollably high calcium-phosphate levels. The most common approach is total parathyroidectomy with auto-transplantation, where all four glands are removed and a small fragment is implanted in the forearm muscle so the body retains some PTH production.
The biggest postoperative challenge is hungry bone syndrome, a rapid and sometimes dangerous drop in blood calcium that occurs because calcium-starved bones suddenly absorb large amounts of calcium and phosphorus from the bloodstream once PTH levels plummet. In one series, roughly a quarter of dialysis patients who underwent total parathyroidectomy developed severe hungry bone syndrome, with calcium levels reaching their lowest point about two weeks after surgery.24PubMed Central. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism Younger age and low preoperative calcium were consistent predictors of who would develop this complication across multiple studies.25PubMed. Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin Patients often require aggressive intravenous calcium supplementation for days to weeks afterward.
What Happens After a Kidney Transplant
A successful kidney transplant restores the ability to activate vitamin D and clear phosphorus, so you might expect secondary hyperparathyroidism to resolve quickly. It often does not. Enlarged parathyroid glands that have been overactive for years do not shrink overnight, and PTH can remain elevated for months or years after transplant. In a study of 143 transplant recipients followed for five years, those whose PTH stayed above roughly 130 ng/L at three months post-transplant had over seven times the risk of fracture compared to patients whose levels normalized.26American Journal of Transplantation. Persistent Hyperparathyroidism After Kidney Transplantation Is Associated With Increased Risk of Fracture
Persistent hyperparathyroidism also appears to threaten the transplanted kidney itself. A separate analysis found that patients with ongoing elevated PTH after transplant had roughly 2.5 times the risk of losing their graft compared to patients whose PTH resolved, and this held true regardless of whether their blood calcium was high or normal.27Annals of Surgery. Resolution of Secondary Hyperparathyroidism After Kidney Transplantation and the Effect on Graft Survival These findings have led to closer PTH monitoring after transplant and, in some cases, parathyroidectomy even after a patient has received a new kidney.
The Overlooked Role of Magnesium
Magnesium deficiency creates a paradox that can confuse the clinical picture of secondary hyperparathyroidism. When magnesium is very low, the parathyroid glands cannot secrete PTH properly, so PTH levels may appear normal or even low despite genuinely low calcium. At the same time, the bones and kidneys become resistant to whatever PTH is circulating, so calcium stays stubbornly low regardless. The result is a patient who is hypocalcemic with an inappropriately low or normal PTH, which looks nothing like secondary hyperparathyroidism on paper but shares the same downstream problem of disordered calcium metabolism.28PubMed. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency
The diagnostic clue is what happens when magnesium is replaced. In magnesium-deficient patients, giving intravenous magnesium triggers an immediate surge in PTH release, a response not seen in people with normal magnesium stores.29The Journal of Clinical Endocrinology & Metabolism. Parathyroid Hormone Secretion in Magnesium Deficiency This matters because magnesium depletion is common in CKD patients (certain diuretics, poor intake, and dialysis itself all contribute), and correcting it can sometimes improve PTH dynamics without any change in calcium or vitamin D therapy. Clinicians who focus exclusively on calcium, phosphorus, and vitamin D while ignoring magnesium may miss a correctable piece of the puzzle.